Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction

Phase 4

Completed

Brief Summary: The present study aimed to evaluate the effect of rosiglitazone treatment on cardiac function compared with metformin

Detailed Description: Large scale clinical trials have reported fluid retention and increase in plasma volume (6% to 7%) with glitazone therapy, with an increased incidence of peripheral edema occuring in 2% to 5% patients. Some evidence suggests that this effect may be related to increased endothelial cell permeability induced by glitazones therapy. Others report that glitazones may interfere with renal hemodynamics. In controlled clinical trials, the frequency of new onset congestive heart failure was very low in glitazones treated patients. The incidence of congestive heart failure is higher in patients receiving combination therapy with insulin and glitazones. Only few studies compared rosiglitazone and metformin on cardiac safety. Recently a study reported a reversible increase in endothelial cell permeability to albumin in cultured pulmonary arterial cells treated with rosiglitazone. To our knowledge, there is not any clinical study published for showing the reversibility of the cardiac adverse effects if the rosiglitazone treatment is continued.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Any known coronary artery disease, congestive hearth failure, renal disease or liver disease
Any treatment for heart failure or diuretics for any reasons.

Primary Outcome Measures

Name	Time	Method
Plasma Brain Natriuretic Peptide levels, echocardiographic measurements were made before the treatment and repeated after three months and six months of the treatment

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial